Clinical trial
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment…
NCT00421304 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00421304 |
|---|---|
| Title | A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized With RSV Illness |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | RSV Illness in ≤12 Months of Participants |
| Intervention type | Biological, Other |
| Interventions | Motavizumab, Placebo |
| Enrollment | 118 |
| Start date | Jan 10, 2007 |
| Primary completion | Sep 17, 2009 |
| Completion | Sep 17, 2009 |
| First posted | Jan 11, 2007 |
| Last update posted | Aug 27, 2021 |
| Countries | Australia, Chile, New Zealand, Panama, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: